APIC

Apic Bio is a clinical-stage gene therapy company focused on developing first-in-class treatments for rare, genetic neurological and liver diseases. The company utilizes its proprietary THRIVE™ platform to design silence and replace therapies that simultaneously knock down a disease-causing gene and deliver a functional copy of the gene using a single AAV vector. Its lead program, APB-102, is currently in clinical development for the treatment of SOD1-linked Amyotrophic Lateral Sclerosis (ALS). Apic Bio was founded by world-renowned experts in gene therapy and neurology from the University of Massachusetts Medical School. The company's approach aims to provide transformative outcomes for patients with limited treatment options by targeting the underlying genetic causes of devastating diseases.